Cyclooxygenase-2 up-regulates ataxia telangiectasia and Rad3 related through extracellular signal-regulated kinase activation

Molecular Cancer Research

Volumn 7, Issue 7, 2009, Pages 1158-1168

  Young, Mee Kim ^a   Eun, Jung Lee ^a   Park, Soo Yeon ^a   Kwan, Ho Cho ^a   Joo, Young Kim ^a   Pyo, Hongryull ^a  

^a National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATR PROTEIN; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

BUTADIENES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DATA INTERPRETATION, STATISTICAL; DINOPROSTONE; DNA DAMAGE; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; NITRILES; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; SIGNAL TRANSDUCTION; SULFONAMIDES; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

ATAXIA TELANGIECTASIA;

EID: 67651148126     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0493     Document Type: Article

References (44)

1. Mannino JL, Kim W, Wernick M, et al. Evidence for alternate splicing within the mRNA transcript encoding the DNA damage response kinase ATR. Gene 2001;272:35-43.
2. Bartek J, Mailand N. TOPping up ATR activity. Cell 2006;124:888-90.
3. Kumagai A, Lee J, Yoo HY, Dunphy WG. TopBP1 activates the ATR-ATRIP complex. Cell 2006;124:943-55.
4. Itakura E, Takai KK, Umeda K, et al. Amino-terminal domain of ATRIP contributes to intranuclear relocation of the ATR-ATRIP complex following DNA damage. FEBS Lett 2004;577:289-93.
5. Jazayeri A, Falck J, Lukas C, et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006;8:37-45.
6. Wang X, Khadpe J, Hu B, Iliakis G, Wang Y. An overactivated ATR/CHK1 pathway is responsible for the prolonged G2 accumulation in irradiated AT cells. J Biol Chem 2003;278:30869-74.
7. Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999;59:4375-82.
8. Tibbetts RS, Cortez D, Brumbaugh KM, et al. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev 2000;14:2989-3002.
9. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007;11:175-89.
10. Adams KE, Medhurst AL, Dart DA, Lakin ND. Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex. Oncogene 2006;25:3894-904.
11. Alderton GK, Galbiati L, Griffith E, et al. Regulation of mitotic entry by microcephalin and its overlap with ATR signalling. Nat Cell Biol 2006;8:725-33.
12. Cortez D, Guntuku S, Qin J, Elledge SJ. ATR and ATRIP: partners in checkpoint signaling. Science (New York) 2001;294:1713-6.
13. Lin JJ, Dutta A. ATR pathway is the primary pathway for activating G2/M checkpoint induction after re-replication. J Biol Chem 2007;282:30357-62.
14. Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 2003;7:207-22.
15. Walch L, Clavarino E, Morris PL. Prostaglandin (PG) FP and EP1 receptors mediate PGF2α and PGE2 regulation of interleukin-1β expression in Leydig cell progenitors. Endocrinology 2003;144:1284-91.
16. Krysan K, Reckamp KL, Dalwadi H, et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 2005;65:6275-81.
17. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007;26:3113-21.
18. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310.
19. Repasky GA, Zhou Y, Morita S, Der CJ. Ras-mediated intestinal epithelial cell transformation requires cyclooxygenase-2-induced prostaglandin E(2) signaling. Mol Carcinog 2007;46:958-70.
20. Sminia P, Kuipers G, Geldof A, Lafleur V, Slotman B. COX-2 inhibitors act as radiosensitizer in tumor treatment. Biomed Pharmacother 2005;59 Suppl 2: S272-5.
21. Ogunwobi OO, Beales IL. Cyclo-oxygenase-independent inhibition of apoptosis and stimulation of proliferation by leptin in human colon cancer cells. Dig Dis Sci 2007;52:1934-45.
22. Steffel J, Akhmedov A, Fahndrich C, Ruschitzka F, Luscher TF, Tanner FC. Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells. Biochem Biophys Res Commun 2006;349:597-603.
23. Yan Y, Black CP, Cowan KH. Irradiation-induced G2/M checkpoint response requires ERK1/2 activation. Oncogene 2007;26:4689-98.
24. Yang HM, Kim HS, Park KW, et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 2004;110:301-8.
25. Shishodia S, Koul D, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-κB activation through inhibition of activation of IκBα kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 2004;173:2011-22.
26. Baek SJ, Wilson LC, Lee CH, Eling TE. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002;301:1126-31.
27. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263-84.
28. Wu D, Chen B, Parihar K, et al. ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function. Oncogene 2006;25:1153-64.
29. Shin YK, Park JS, Kim HS, et al. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 2005;65:9501-9.
30. Ozeri-Galai E, Schwartz M, Rahat A, Kerem B. Interplay between ATM and ATR in the regulation of common fragile site stability. Oncogene 2007.
31. Bakkenist CJ, Kastan MB. Initiating cellular stress responses. Cell 2004;118:9-17.
32. Kumar S, Dodson GE, Trinh A, Puchalski JR, Tibbetts RS. ATR activation necessary but not sufficient for p53 induction and apoptosis in hydroxyurea-hypersensitive myeloid leukemia cells. Cell Cycle 2005;4:1667-74.
33. Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 2006;26:7529-38.
34. Bennett LN, Clarke PR. Regulation of Claspin degradation by the ubiquitinproteosome pathway during the cell cycle and in response to ATR-dependent checkpoint activation. FEBS Lett 2006;580:4176-81.
35. Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis 2006;21:3-9.
36. Nghiem P, Park PK, Kim YS, Desai BN, Schreiber SL. ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint. J Biol Chem 2002;277:4428-34.
37. Xu B, Kim ST, Lim DS, Kastan MB. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol 2002;22:1049-59.
38. Soutoglou E, Misteli T. Activation of the cellular DNA damage response in the absence of DNA lesions. Science (New York) 2008;320:1507-10.
39. Yang J, Yu Y, Hamrick HE, Duerksen-Hughes PJ. ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis 2003;24:1571-80.
40. Yang J, Xu ZP, Huang Y, Hamrick HE, Duerksen-Hughes PJ, Yu YN. ATM and ATR: sensing DNA damage. World J Gastroenterol 2004;10:155-60.
41. Chae HJ, Chae SW, Reed JC, Kim HR. Salicylate regulates COX-2 expression through ERK and subsequent NF-κB activation in osteoblasts. Immunopharmacol Immunotoxicol 2004;26:75-91.
42. Funakoshi M, Tago K, Sonoda Y, Tominaga S, Kasahara T. A MEK inhibitor, PD98059 enhances IL-1-induced NF-κB activation by the enhanced and sustained degradation of IκBα. Biochem Biophys Res Commun 2001;283:248-54.
43. Kang HK, Lee E, Pyo H, Lim SJ. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther 2005;4:1358-63.
44. Lee SY, Song EJ, Kim HJ, Kang HJ, Kim JH, Lee KJ. Rac1 regulates heat shock responses by reorganization of vimentin filaments: identification using MALDI-TOF MS. Cell Death Differ 2001;8:1093-102.